Founded in 2014, NeuCen Biomed. Inc. aims to improve the health and well-being of patients.  We develop products for cancer and immune-related diseases of high incidence among Chinese in the Asia-Pacific region, focusing on new drug innovation, drug delivery innovation, safety and efficacy, and medication convenience.

Through the integration of outstanding technical team partners, from domestic and abroad, including NeOnc Technology Inc. in the United States; Taichung Veteran General Hospital, the Biotechnology Development Center and Chenggong University in Taiwan, we will jointly develop new drug products that lead the market. NeuCen Biomed. Inc. holds a number of patents, including new drugs for allergic rhinitis, new drugs for nasopharyngeal cancer/breast cancer/prostate cancer/colorectal cancer, etc. The new drug products currently under active development include a new drug for the treatment of allergic rhinitis and a new drug for nasopharyngeal cancer, which is expected to enter the IND (new drug clinical trial) stage in the fourth quarter of 2022.

NeuCen Biomed. shortens the research and development time and diversifies the research and development risks through the R&D strategy and technical cooperation developed with industry, government, academia and research. The research and development will focus on the development of new cancer drugs, clinical trials and technology transfer, the search and verification of target drugs, the discussion of biological functions, and the feasibility assessment of new product development.